Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotic therapies for stroke prevention

D H Solomon1, R G Hart

  • 1Department of Medicine, University of Texas Health Science Center, San Antonio 78284.

Current Opinion in Neurology
|February 1, 1994
PubMed
Summary

Aspirin is a common antiplatelet drug for stroke prevention. Its effectiveness may differ by stroke cause, and alternative treatments like ticlopidine or warfarin are considered for specific patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Duration and dose of allopurinol needed to attain the serum urate target in gout.

Scandinavian journal of rheumatology·2026
Same author

No association between vascular inflammation and estimated glomerular filtration rate in patients with rheumatoid arthritis: secondary analysis of the TARGET trial.

Scandinavian journal of rheumatology·2025
Same author

Associations among temporal and large artery abnormalities on vascular ultrasound in giant cell arteritis.

Scandinavian journal of rheumatology·2021
Same author

Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide.

Scandinavian journal of rheumatology·2020
Same author

Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.

European journal of neurology·2020
Same author

Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees.

Osteoarthritis and cartilage·2019

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Aspirin is the leading antiplatelet medication for preventing ischemic stroke.
  • Stroke etiology may influence aspirin's therapeutic efficacy.
  • Alternative antiplatelet agents and anticoagulants are crucial for specific patient populations.

Purpose of the Study:

  • To review the varying efficacy of aspirin based on stroke subtype.
  • To discuss alternative therapies for patients intolerant to aspirin or experiencing stroke during aspirin treatment.
  • To examine prophylactic treatments for atrial fibrillation-associated stroke.

Main Methods:

  • Literature review of clinical evidence on antiplatelet and anticoagulant therapies for stroke prevention.
  • Analysis of studies comparing aspirin, ticlopidine, and warfarin efficacy and safety.

Related Experiment Videos

  • Identification of clinical and echocardiographic predictors for thromboembolic risk in atrial fibrillation.

    • Main Results:

    • Aspirin reduces nonfatal ischemic stroke by 22%.
    • Ticlopidine is an alternative for aspirin-intolerant patients or those with aspirin treatment failure.
    • Warfarin is more effective than aspirin for atrial fibrillation-associated stroke, but carries higher bleeding risks and requires monitoring.

    Conclusions:

    • Treatment choice for stroke prevention should consider stroke etiology and patient-specific factors.
    • Warfarin and aspirin are indicated for atrial fibrillation, with risk-benefit analysis guiding selection.
    • Identifying thromboembolic risk factors in atrial fibrillation can personalize prophylactic treatment strategies.